

IN THE CLAIMS

Please substitute the claim set below for the previous claim set. The claim set below therefore replaces all prior versions and listings of claims in the above-identified application.

Claim 1. (Cancelled)

Claim 2. (Currently amended) The oligonucleotide of claim + 6 or 7, wherein the antisense nucleic acid is about 20 nucleotides in length.

Claim 3. (Currently amended) The oligonucleotide of claim + 6 or 7, wherein the antisense nucleic acid sequence is phosphorothiolated.

Claim 4. (Cancelled)

Claim 5. (Currently amended) The oligonucleotide of claim + 6 or 7, wherein the antioxidant enzyme is catalase or phospholipid glutathione peroxidase.

Claim 6. (Currently amended) The oligonucleotide of claim + An oligonucleotide comprising an antisense nucleic acid sequence that specifically binds to a nucleic acid encoding a human antioxidant enzyme start codon, wherein the antisense sequence is about 18 to 26 nucleotides in length, and wherein the antioxidant enzyme is manganese superoxide dismutase, copper and zinc superoxide dismutase, catalase, phospholipid glutathione peroxidase, or cytosolic glutathione peroxidase, wherein the antisense nucleic acid sequence is 90% complementary to [90%] a portion of the nucleic acid encoding an antioxidant enzyme.

Claim 7. (Currently amended) The oligonucleotide of claim + An oligonucleotide comprising an antisense nucleic acid sequence that specifically binds to a nucleic acid encoding a human antioxidant enzyme start codon, wherein the antisense

sequence is about 18 to 26 nucleotides in length, and wherein the antioxidant enzyme is manganese superoxide dismutase, copper and zinc superoxide dismutase, catalase, phospholipid glutathione peroxidase, or cytosolic glutathione peroxidase, wherein the antisense nucleic acid sequence is 100% complementary to [100%] a portion of the nucleic acid encoding an antioxidant enzyme.

Claim 8. (Currently amended) A method of treating a tumor in a mammal comprising reducing antioxidant enzyme levels in a cell by administering a therapeutic agent comprising an antisense nucleic acid sequence that specifically binds to a nucleic acid encoding [an] a human antioxidant enzyme start codon, wherein the antisense sequence is about 18 to 26 nucleotides in length, and wherein the antioxidant enzyme is manganese superoxide dismutase, copper and zinc superoxide dismutase, catalase, phospholipid glutathione peroxidase, or cytosolic glutathione peroxidase.

Claims 9-10. (Cancelled)

Claim 11. (Previously presented) The method of claim 8, wherein the therapeutic agent is injected into the tumor.

Claim 12. (Original) The method of claim 8, wherein the mammal is a human.

Claim 13. (Original) The method of claim 8, wherein the therapeutic agent further comprises a delivery vehicle.

Claim 14. (Original) The method of claim 13, wherein the delivery vehicle is lipofectamine or -[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate (“DOTAP”).

Claim 15. (Previously presented) The method of claim 8, wherein the antisense nucleic acid sequence is phosphorothiolated.

Claim 16. (Cancelled)

Claim 17. (Currently amended) The method of claim 8 +6, wherein the antioxidant enzyme is manganese superoxide dismutase, catalase, or phospholipid glutathione peroxidase.

Claim 18. (Currently amended) The method of claim 8, wherein the antisense nucleic acid sequence is 90% complementary to [90%] a portion of the nucleic acid encoding an antioxidant enzyme.

Claim 19. (Currently amended) The method of claim 8, wherein the antisense nucleic acid sequence is 100% complementary to [100%] a portion of the nucleic acid encoding an antioxidant enzyme.

Claim 20. (Currently amended) An oligonucleotide comprising an antisense nucleic acid sequence that specifically binds to a nucleic acid encoding an antioxidant enzyme start codon, wherein the sequence is SEQ ID NO:1, 2 or 3 SEQ ID NO:2.

Claim 21. (Previously presented) The oligonucleotide of claim 20, wherein the antisense nucleic acid sequence is phosphorothiolated.

Claim 22. (New) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is manganese superoxide dismutase.

Claim 23. (New) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is copper and zinc superoxide dismutase.

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Serial Number: 09/993,333

Filing Date: November 14, 2001

Title: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING ANTISENSE OLIGONUCLEOTIDES

Page 5
Dkt: 875.042US1

Claim 24. (New) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is catalase.

Claim 25. (New) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is phospholipid glutathione peroxidase.

Claim 26. (New) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is cytosolic glutathione peroxidase.